Tag: common share

Second Quarter 2026

TORONTO, July 22, 2026 (GLOBE NEWSWIRE) -- STORAGEVAULT CANADA INC. (“StorageVault” or the “Corporation”) (SVI-TSX) reports the Corporation’s Q2 2026 results. Iqbal Khan, Chief Financial Officer, commented:

HOUSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) ("Crown Castle") today reported results for the second quarter ended June 30, 2026, and updated its full year 2026 Outlook, as reflected in the table below.

VERO BEACH, Florida, July 22, 2026 (GLOBE NEWSWIRE) -- ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR PRC) (“ARMOUR” or the “Company”) today announced the Company's unaudited Q2 results and June 30, 2026 financial position.

TORONTO, June 26, 2026 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR), today announced that the Toronto Stock Exchange (the “TSX”) has approved the Company’s notice of intention to renew its normal course issuer bid (the “NCIB”) for common shares of the Company (the “Common Shares”).

CALGARY, Alberta, June 25, 2026 (GLOBE NEWSWIRE) -- Petrus Resources Ltd. ("Petrus") (TSX: PRQ) is pleased to announce that the Toronto Stock Exchange (the "TSX") has accepted Petrus' notice of intention to renew its normal course issuer bid (the "NCIB"). The NCIB allows Petrus to purchase up to 7,424,183 common shares (representing 5% of Petrus' outstanding common shares as of June 19, 2026) over a period of twelve months commencing on June 30, 2026. On June 19, 2026, Petrus had 148,483,679 common shares outstanding. The NCIB will expire no later than June 29, 2027.

VERO BEACH, Florida, June 24, 2026 (GLOBE NEWSWIRE) -- ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced guidance on the July 2026 cash dividend for the Company's Common Stock of $0.24 per Common share.

Fiscal 2026 Net Income Expected Between $15 Million and $18 Million
Adjusted EBITDA Expected between $75 Million and $77 Million, an increase of 26% to 30%
First Day Program Revenues Estimated to Increase 27% to 28%
Board of Directors Declares Quarterly Dividend of $0.08 per Common Share

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).